2011
DOI: 10.1111/j.1365-2796.2011.02376.x
|View full text |Cite
|
Sign up to set email alerts
|

Novel therapies for coeliac disease

Abstract: Coeliac disease is a widespread, lifelong disorder for which dietary control represents the only accepted form of therapy. There is an unmet need for non-dietary therapies to treat this condition. Most ongoing and emerging drug discovery programmes are based on the understanding that coeliac disease is caused by an inappropriate T-cell-mediated immune response to dietary gluten proteins. Recent genome-wide association studies lend further support to this pathogenic model. The central role of human leukocyte an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
85
0
8

Year Published

2012
2012
2018
2018

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 113 publications
(94 citation statements)
references
References 91 publications
1
85
0
8
Order By: Relevance
“…More than 90% of CD patients express HLA-DQ2; the others express HLA-DQ8 (8). In view of the high frequency of HLA-DQ2 in controls (about 30%), HLA-DQ2 or DQ8 genes are necessary but not sufficient for the development of the disease (23,24). The HLAand non-HLA-genes identified to modulate the probability of developing CD contribute around 50% to the disease risk (16).…”
Section: Symptoms and Diagnosticsmentioning
confidence: 99%
See 1 more Smart Citation
“…More than 90% of CD patients express HLA-DQ2; the others express HLA-DQ8 (8). In view of the high frequency of HLA-DQ2 in controls (about 30%), HLA-DQ2 or DQ8 genes are necessary but not sufficient for the development of the disease (23,24). The HLAand non-HLA-genes identified to modulate the probability of developing CD contribute around 50% to the disease risk (16).…”
Section: Symptoms and Diagnosticsmentioning
confidence: 99%
“…Budesonide, a glucocorticoid with low oral bioavailability, was clinically beneficial for refractory (i.e., non-responsive to a GFD) and non-refractory CD (61,62). Its use in CD would require a formulation targeting the proximal small intestine given that budesonide is currently mostly used for inflammatory bowel diseases affecting the ileum and colon (24). Several proinflammatory cytokines and lymphocyte-recruiting chemokines (e.g., TNFα, IFNγ, IL-15, CCL25, CXCL10) were recently identified to be particularly relevant in CD (31).…”
Section: Anti-inflammatory Therapymentioning
confidence: 99%
“…The mechanism by which TG2 is activated in the celiac small intestine remains unknown. A better understanding of this mechanism could facilitate the discovery of drugs that protect celiac patients from gluten-induced immunotoxicity by blocking TG2 activity in the small intestine (Sollid and Khosla, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…During the years, non-dietary treatments were investigated but the results were discouraging (Sollid 2011, Plugis 2015, Dielli-Crimi 2015. GFD meant initially abstention from wheat, barley, rye and oats.…”
Section: Treatment Gfd: Now and Then-oatsmentioning
confidence: 99%